Novel pharmacological approaches in migraine therapy

On September 19th and 20th, 2024, the University of Calabria, Rende (Cosenza) was venue of the congress “Novel Pharmacological Approaches in Migraine Therapy”. The latter represented a collaborative scientific initiative of the University of Calabria (Cosenza), University Magna Graecia
(Catanzaro), and Sant’Anna Institute (Crotone) under the Auspices of NEXT GENERATION EU (NGEU), the Ministry of University and Research (MUR), National Recovery and Resilience Plan (NRRP), project Mnesys (PE0000006), the Italian Society of Pharmacology (SIF), the Italian Society of Neuroscience (SINS), the Italian Society for the Study of Headache (SISC), the Italian Society of Neurological Rehabilitation (SIRN), and the Italian Society of Child and Adolescent Neuropsychiatry (SINPIA). The meeting was organized by Professors Antonio Leo and Damiana Scuteri and chaired by Professors Giacinto Bagetta, Maria Tiziana Corasaniti and Giovambattista De Sarro.

Migraine represents one of the most disabling forms of primary headache, with a severe social impact, rank as one of the leading causes of years lived with disability worldwide and therefore considered a very serious public health problem.
Migraine constitutes a substantial public health problem that mainly affects young and middle-aged adults. As widely reported, migraine is often associated to various comorbidities, including epilepsy, attention-deficit hyperactivity disorder, behavioral problems, obesity, atopic dermatitis, asthma, restless legs syndrome, and anemia that negatively impact the quality of life of patients, increasing further the use of health care and medication.
Professor Paolo Martelletti (Rome) pointed at the need for training of young physicians in the clinical practice of migraine management. Particularly, Dr Angelo Pascarella (Catanzaro) described how migraine and epilepsy share several clinical features and have intertwined genetic and molecular underpinnings, which may contribute to common pathogenesis.

Read the full text below